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Allopurinol
A New Anti-Ischemic
Role for an Old Drug*
Peter H. Stone, MD
Boston, Massachusetts
Pharmacologic treatment of stable ischemic heart disease
has, until recently, been limited to the traditional agents
that primarily improve the myocardial oxygen (O2) supply/
demand balance by reducing myocardial O2 demand (1).
eta-adrenergic blockers, nitrates, and calcium channel
lockers have been the mainstays of such therapeutic strat-
gies and they have enabled patients with a flow-limiting fixed
uminal obstruction to increase their exercise capacity by
educing heart rate, blood pressure, and/or myocardial contrac-
ility. Because such therapy typically does not enhance myo-
ardial blood flow, the maximum tolerated rate pressure prod-
ct (heart rate  systolic blood pressure)—the routine marker
f myocardial O2 demand—does not change during active
herapy; the patient can simply exercise for longer duration
ntil that peak rate pressure product is achieved (2).
See page 820
New antianginal and anti-ischemic therapies have become
available in recent years that use different mechanisms of action
and seem to expand the pharmacological approach available to
treat patients with coronary artery disease (CAD). For exam-
ple, ranolazine exerts an anti-ischemic effect by reducing late
sodium influx and, consequently, calcium influx into myocar-
dial cells during ischemia and thereby reduces diastolic myo-
cardial tension and preserves local flow in ischemic zones (3).
rimetazidine modulates myocardial metabolism by partially
nhibiting free fatty acid as an energy source and enhances
lucose use, which requires less O2 than free fatty acid use (4).
Nicorandil activates adenosine triphosphate-sensitive potas-
sium channels and pharmacologically induces a state that
mimics ischemic pre-conditioning, and it also dilates coronary
resistance arterioles (5).
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Sciences.To this list of novel anti-ischemia therapies now comes
allopurinol, a medication that has been used since the mid-
1960s for the treatment of gout. Allopurinol inhibits xanthine
oxidase (XO), a potent mediator of oxidative stress (6,7), and
consequently significantly reduces tissue oxidative stress (8,9).
The first application of allopurinol-associated improve-
ment in oxidative stress was as a novel therapy for congestive
heart failure (CHF), since the improvement in myocardial
oxidative stress enhances myofilament responsiveness to acti-
vator calcium (8,10) and consequently improves the impaired
myocardial energy use fundamental to heart failure (11). Acute
and chronic administration of allopurinol increases myocardial
contractility in experimental animals with heart failure, while
simultaneously reducing myocardial O2 consumption, and also
rolongs survival (8,12). A recent large-scale clinical trial,
owever, did not confirm the benefit of allopurinol to improve
he outcomes of unselected patients with symptomatic CHF
13), although the dose of the XO inhibitor and the duration
f follow-up might have been inadequate (14).
Vascular oxidative stress is also a fundamental pathobiologi-
al manifestation of CAD, and allopurinol has been shown to
mprove vascular oxidative stress and endothelial function in
atients with CAD (15). Therefore, allopurinol has recently
een investigated in the treatment of stable ischemic heart
isease, and the early results have indeed been encouraging.
dministration of allopurinol 600 mg/day in a double-blind
rossover design to 65 patients with stable CAD, ejection
raction 45%, and provokable ischemia despite optimal
nti-ischemic medications (16) was associated with a 43-s
edian increase in exercise time to ST-segment depression
p  0.0002), a 58-s median increase in total exercise time
p 0.0003), and a 38-s median increase in time to chest pain
p  0.001). Maximum tolerated rate pressure product was
ignificantly, although only slightly, higher on allopurinol
ompared with placebo. The specific mechanisms of benefit
ere not studied in that trial, but the investigators speculated
hat the anti-ischemic mechanism was not related to a reduc-
ion in myocardial O2 demand but instead to an improvement
in myocardial O2 use or to an improvement in endothelial
unction and, consequently, an improvement in myocardial
lood flow.
In this issue of the Journal, Rajendra et al. (17) from the
ame group now focus on the potential mechanism of the
nti-ischemic effect of allopurinol. They studied 80 patients
ith stable CAD who were treated with conventional anti-
schemic and vasculoprotective agents, including beta-blockers,
tatins, angiotensin-converting enzyme inhibitors/angiotensin
eceptor blockers, and dual antiplatelet therapy. They admin-
stered high-dose allopurinol (600 mg/day) or placebo in a
rossover design, assessed vascular oxidative stress with intra-
rterial coinfusion of vitamin C and acetylcholine, and assessed
ndothelial function with forearm venous occlusion plethys-
ography, flow-mediated dilation, and pulsed wave analysis.
hey observed that allopurinol abolished vascular oxidative
tress and improved endothelial-dependent vasodilation. The
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also significantly improved with allopurinol but not with
placebo. The authors speculate that the improvement in
vascular function was likely responsible for the increased
exercise performance that was previously observed (16). They
then extrapolate further and suggest that the improved endo-
thelial function by allopurinol might also improve survival in
patients with CAD.
How do we best position allopurinol in our armamentarium
for patients with stable CAD at this time? And what is the
most likely beneficial mechanism of action? The observed
benefit on vascular oxidative stress, endothelial function, and
likely enhanced coronary blood flow as well as the potential
improvement in myocardial oxidative stress may well be the
responsible mechanisms for the benefit of allopurinol in exer-
cise tolerance and the increase in the maximum tolerated rate
pressure product (16). The single exercise test study (16) was
quite small, however, and will need to be repeated, and the
benefit and the putative mechanism of action will need to be
confirmed. The anti-ischemic effect of allopurinol occurred
without a major effect on the myocardial O2 demand determi-
ants and indicates that allopurinol could be complementary to
ther anti-ischemic medications and could be used safely in
ombination regimens or when other anti-ischemic agents
ight not be tolerated because of excessive hemodynamic or
lectrophysiological effects.
Although it is tantalizing to speculate that the marked effect
f allopurinol to reduce vascular oxidative stress will translate
nto clinical vascular protection and a role in routine secondary
revention, it is a substantial leap at this time to assume that
he observed benefit of allopurinol on endothelium-dependent
asomotion will translate into an improvement in the funda-
ental pathobiology of atherosclerosis that renders a high-risk
oronary plaque likely to rupture. Mortality in CAD patients is
rimarily related to plaque rupture or erosion, leading to
uperimposed thrombus formation and precipitation of an
cute coronary syndrome, and not to endothelial dysfunction
nd abnormal coronary vasomotion. Although allopurinol
educes vascular oxidative stress, its therapeutic effects on the
ocal behavior within advanced, complicated atherosclerotic
laque need to be investigated.
Lastly, we need to be attentive to the dose and side effects
f allopurinol for treatment of CAD. The standard dose of
llopurinol for the treatment of gout is generally 300
g/day, whereas the dose used for the stable angina studies
escribed in the preceding text is 600 mg/day. Allopurinol
an cause hypersensitivity and cutaneous adverse reactions,
ncluding the very rare Stevens-Johnson syndrome and toxic
pidermal necrolysis, which are thought to be more com-
on with higher doses of allopurinol or in the setting of
enal dysfunction (18). It will be important to determine the
ost appropriate dose of allopurinol for CAD patients and
hat dose adjustments need to be made for patients with
ecreased renal function.
Optimism is certainly appropriate for use of allopurinol as annti-ischemic agent for stable CAD (7), even if the specific sechanism of action of its benefit remains unclear. The
agnitude of its clinical benefit seems to be similar to that of
ther more conventional anti-ischemic agents. Whether allo-
urinol will also be of value for vascular protection and
econdary prevention will require more dedicated study.
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